IGM Biosciences Statistics
Share Statistics
IGM Biosciences has 66.92M shares outstanding. The number of shares has increased by 80.33% in one year.
| Shares Outstanding | 66.92M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.5% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 30.69M |
| Failed to Deliver (FTD) Shares | 80 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 3.37M, so 5.66% of the outstanding shares have been sold short.
| Short Interest | 3.37M |
| Short % of Shares Out | 5.66% |
| Short % of Float | 10.97% |
| Short Ratio (days to cover) | 11.83 |
Valuation Ratios
The PE ratio is -1.76 and the forward PE ratio is -4.73.
| PE Ratio | -1.76 |
| Forward PE | -4.73 |
| PS Ratio | 204.09 |
| Forward PS | 70.2 |
| PB Ratio | 2.14 |
| P/FCF Ratio | -2.12 |
| PEG Ratio | n/a |
Enterprise Valuation
IGM Biosciences Inc. has an Enterprise Value (EV) of 362.11M.
| EV / Earnings | -1.47 |
| EV / Sales | 170 |
| EV / EBITDA | -1.43 |
| EV / EBIT | -1.37 |
| EV / FCF | -1.77 |
Financial Position
The company has a current ratio of 8.18, with a Debt / Equity ratio of 0.03.
| Current Ratio | 8.18 |
| Quick Ratio | 8.18 |
| Debt / Equity | 0.03 |
| Total Debt / Capitalization | 2.79 |
| Cash Flow / Debt | -32.95 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.21% and return on capital (ROIC) is -108.39%.
| Return on Equity (ROE) | -1.21% |
| Return on Assets (ROA) | -0.58% |
| Return on Capital (ROIC) | -108.39% |
| Revenue Per Employee | 10.76K |
| Profits Per Employee | -1.24M |
| Employee Count | 198 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 678.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 13.94% in the last 52 weeks. The beta is 0.19, so IGM Biosciences 's price volatility has been higher than the market average.
| Beta | 0.19 |
| 52-Week Price Change | 13.94% |
| 50-Day Moving Average | 12.85 |
| 200-Day Moving Average | 10.69 |
| Relative Strength Index (RSI) | 29.3 |
| Average Volume (20 Days) | 315.64K |
Income Statement
In the last 12 months, IGM Biosciences had revenue of $2.13M and earned -$246.42M in profits. Earnings per share was $-4.71.
| Revenue | 2.13M |
| Gross Profit | -6.15M |
| Operating Income | -263.46M |
| Net Income | -246.42M |
| EBITDA | -253.36M |
| EBIT | -263.46M |
| Earnings Per Share (EPS) | -4.71 |
Balance Sheet
The company has $112.52M in cash and $40.51M in debt, giving a net cash position of $72.01M.
| Cash & Cash Equivalents | 112.52M |
| Total Debt | 40.51M |
| Net Cash | 72.01M |
| Retained Earnings | -821.24M |
| Total Assets | 304.51M |
| Working Capital | 185.67M |
Cash Flow
In the last 12 months, operating cash flow was -$192.23M and capital expenditures -$12.38M, giving a free cash flow of -$204.61M.
| Operating Cash Flow | -192.23M |
| Capital Expenditures | -12.38M |
| Free Cash Flow | -204.61M |
| FCF Per Share | -3.91 |
Margins
Gross margin is -288.59%, with operating and profit margins of -12.37K% and -11.57K%.
| Gross Margin | -288.59% |
| Operating Margin | -12.37K% |
| Pretax Margin | -11.54K% |
| Profit Margin | -11.57K% |
| EBITDA Margin | -11.89K% |
| EBIT Margin | -12.37K% |
| FCF Margin | -9.61K% |
Dividends & Yields
IGMS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -62.63% |
| FCF Yield | -40.66% |
Analyst Forecast
The average price target for IGMS is $20, which is 166% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 166% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -4.89 |
| Piotroski F-Score | 3 |